Table 1 Trial and patient summary characteristics for the 102 eligible RCTs (36,058 patients) of second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR
Trial characteristics | No. of trials (%) |
|---|---|
Phase of trial | |
II | 48 (47) |
III | 53 (52) |
Unclear | 1 (1) |
No. of centers | |
Multi-center | 88 (86) |
Single-center | 7 (7) |
Unclear | 7 (7) |
Funding source | |
Industry | 69 (68) |
Non-industry | 13 (13) |
Both | 2 (2) |
Not reported | 18 (17) |
No. of patients (median [Q1–Q3]; mean) | 167 [105–528]; 354 |
Line therapy | |
Second-line only | 50 (49) |
Second- and third-line | 41 (40) |
Proportion of patients with third-line therapya | 31% |
Not specified | 11 (11) |
Population characteristics | |
Geographic origin | |
Most Western patientsb | 54 (53) |
Asian patients only | 26 (25) |
Not specified | 22 (22) |
Proportion of Asian patientsa | 14% |
Trials in specific histology subtype | |
NSCC | 20 (20) |
SCC | 4 (4) |
Proportion of patients with SCCa | 27% |
Molecular characteristics at baseline | |
Unknown status for EGFR | 93 (91) |
EGFR wild-type | 6 (6) |
KRAS mutation | 3 (3) |
Patient characteristicsa | |
Age, years | 61 |
Male | 62% |
Stage IV cancer | 81% |
Patients PS 2 | 8% |
Former or current smoker | 80% |
Patients receiving second-line treatment | 85% |